9.51

1.49% 0.14

After Hours: 9.51

Bioventus Inc (BVS)

Overview News Price History Option Chain Financials Discussions Forecast

Bioventus Inc stock is traded at $9.51, with a volume of 218.30K. It is up +1.49% in the last 24 hours and down -6.21% over the past month. Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.

Previous Close:

$9.37

Open:

$9.31

24h Volume:

218.30K

Relative Volume:

0.71

Market Cap:

$619.89M

Revenue:

$555.06M

Net Income/Loss:

$-39.48M

P/E Ratio:

-15.85

EPS:

-0.6

Net Cash Flow:

$29.05M

1W Performance:

+4.28%

1M Performance:

-6.21%

6M Performance:

-19.27%

1Y Performance:

+88.69%

1-Day Range:

$9.16

$9.56

1-Week Range:

$8.78

$9.56

52-Week Range:

$3.90

$14.38

Bioventus Inc Stock (BVS) Company Profile

Name

Bioventus Inc

Sector

Healthcare (1183)

Industry

Medical Devices (160)

Phone

(919) 474-6700

Address

4721 EMPEROR BOULEVARD, SUITE 100, DURHAM

Employee

930

Twitter

Next Earnings Date

2025-03-11

Latest SEC Filings

BVS's Discussions on Twitter

Compare BVS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BVS Bioventus Inc	9.51	619.89M	555.06M	-39.48M	29.05M	-0.60
ABT Abbott Laboratories	131.93	225.32B	41.95B	13.40B	6.35B	7.65
BSX Boston Scientific Corp	100.05	149.74B	16.75B	1.85B	2.37B	1.25
SYK Stryker Corp	377.46	142.48B	22.60B	2.99B	3.49B	7.76
MDT Medtronic Plc	88.86	113.49B	33.20B	4.26B	5.47B	3.29
EW Edwards Lifesciences Corp	72.05	42.10B	5.72B	4.17B	259.90M	6.97

Bioventus Inc Stock (BVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-17-24	Upgrade	JP Morgan	Underweight → Neutral
Dec-07-23	Upgrade	Canaccord Genuity	Hold → Buy
Aug-09-23	Upgrade	Craig Hallum	Hold → Buy
Nov-22-22	Downgrade	Craig Hallum	Buy → Hold
Nov-09-22	Downgrade	Canaccord Genuity	Buy → Hold
Nov-09-22	Downgrade	JP Morgan	Overweight → Underweight
Mar-15-22	Initiated	Craig Hallum	Buy
Nov-15-21	Resumed	Morgan Stanley	Overweight
Nov-10-21	Resumed	JP Morgan	Overweight
Jul-01-21	Downgrade	Goldman	Buy → Neutral
Mar-08-21	Initiated	Canaccord Genuity	Buy
Mar-08-21	Initiated	Goldman	Buy
Mar-08-21	Initiated	JP Morgan	Overweight
Mar-08-21	Initiated	Morgan Stanley	Overweight

View All

Bioventus Inc Stock (BVS) Latest News

Apr 01, 2025

Canaccord maintains Bioventus stock with $15 target, bullish outlook - Investing.com India

Apr 01, 2025

Mar 31, 2025

Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance

Mar 31, 2025

Bone Growth Stimulator Market Is Booming Worldwide | Orthofix Medical Inc., Medtronic, Zimmer Biomet, Bioventus Inc - openPR.com

Mar 31, 2025

Mar 26, 2025

Charles Schwab Investment Management Inc. Grows Position in Bioventus Inc. (NYSE:BVS) - Defense World

Mar 26, 2025

Mar 25, 2025

Bioventus CFO Mark Leonard sells $53,639 in stock By Investing.com - Investing.com Australia

Mar 25, 2025

Bioventus SVP Katrina Church sells shares worth $9,925 By Investing.com - Investing.com Australia

Mar 18, 2025

Bioventus SVP Anthony D’Adamio sells $25,496 in stock - Investing.com India

Mar 18, 2025

Bioventus SVP Katrina Church sells shares worth $9,925 - Investing.com India

Mar 18, 2025

Europe Viscosupplementation Market Projected To Witness Substantial Growth, 2025-2032: Sanofi S.A., Bioventus - EIN News

Mar 18, 2025

Bioventus (NYSE:BVS) Receives “Buy” Rating from Canaccord Genuity Group - Defense World

Mar 18, 2025

Mar 17, 2025

Bioventus (BVS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Mar 17, 2025

Mar 14, 2025

How To Trade (BVS) - news.stocktradersdaily.com

Mar 14, 2025

Earnings call transcript: Bioventus Q4 2024 beats revenue forecast, stock surges - Investing.com Australia

Mar 14, 2025

Mar 12, 2025

Bioventus Earnings Call: Strong Growth & 2025 Outlook - TipRanks

Mar 12, 2025

Bioventus Inc. (NASDAQ:BVS) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 12, 2025

Bioventus: Strong Financial Performance and Strategic Growth Drive Buy Rating - TipRanks

Mar 12, 2025

Bioventus Full Year 2024 Earnings: Beats Expectations - Yahoo

Mar 12, 2025

Bioventus Faces Potential Stock Dilution Risk Amid Resale of 35 Million Shares - TipRanks

Mar 12, 2025